| abstract |
The present invention relates to 2- [4- (1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl) phenoxymethyl] quinoline or a pharmaceutically acceptable salt thereof, as well as 2 - [- 4- (4 -pyridin-4-yl-2H-pyrazol-3-yl) phenoxymethyl] quinoline and 2- [4- (2-methyl-4-pyridin-4-yl-2H-pyrazol-3-yl) phenoxymethyl] quinoline, and their pharmaceutically acceptable salts, which serve as effective phosphodiesterase (PDE) inhibitors. In particular, the present invention relates to these compounds, which are selective PDE10 inhibitors. The present invention also relates to pharmaceutical compositions comprising said compounds; and the use of these compounds in a method of treating a number of diseases of the central nervous system (CNS) or other disorders. |